Given this and combined with our current results, which points towards a role of caspase-2 and caspase-3 in GO-induced apoptosis in AML cells, we next analysed whether full-length caspase-2 or caspase-3 expression levels prior treatment could be linked to CR duration in an AML patient cohort (n = 22) treated with conventional chemotherapy regiments. The gene discussed is CASP2; the disease is acute myeloid leukemia.